5月14日 - ** 药物开发商Septerna SEPN.O的股价盘前上涨63.3%至10.99美元
** 丹麦制药商诺和诺德NOVOb.CO与SEPN合作开发治疗肥胖症和糖尿病的口服药物，交易价值高达22亿美元 (link)。
** 交易包括向SEPN支付超过2亿美元的预付款和近期付款
** 两家公司计划启动四个潜在新疗法的开发项目
** 两家公司表示，合作旨在开发针对特定蛋白质的新药，以帮助新陈代谢和其他身体机能的恢复
** 截至上次收盘，SEPN累计下跌70.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.